Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Cyclooxygenase-2-specific inhibitors: Are they safe?
Thomas J. Schnitzer
*
*
Corresponding author for this work
Medicine
Research output
:
Contribution to journal
›
Review article
›
peer-review
47
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cyclooxygenase-2-specific inhibitors: Are they safe?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Specific Inhibitor
100%
Platelets
100%
Cyclooxygenase-1 (COX-1)
100%
Cyclooxygenase-2
100%
Cyclooxygenase-2 Inhibitors
100%
Clinical Trials
50%
Kidney
50%
Increased Incidence
50%
Wound Healing
50%
Endothelial Function
50%
Clinical State
50%
Reproductive Function
50%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
50%
Controlled Experiment
50%
Physiological Function
50%
Stomach
50%
Hypertension Incidence
50%
Edema
50%
Gastrointestinal Safety
50%
Clinically Meaningful Outcomes
50%
COX Inhibitors
50%
Medicine and Dentistry
Platelet
100%
Cyclooxygenase 2
100%
Cyclooxygenase 2 Inhibitor
100%
Side Effect
50%
Edema
50%
Wound Healing
50%
Controlled Clinical Trial
50%
Nonsteroid Antiinflammatory Agent
50%
Reproductive Medicine
50%
Endothelial Function
50%
Clinical Trial
50%
Methapyrilene
50%
Pharmacology, Toxicology and Pharmaceutical Science
COX-2 Inhibitor
100%
Cyclooxygenase 2
100%
Controlled Clinical Trial
50%
Clinical Trial
50%
Side Effect
50%
Non-Steroidal Anti-Inflammatory Drug
50%
Wound Healing
50%
Methapyrilene
50%
Edema
50%
Nursing and Health Professions
Cyclooxygenase 2 Inhibitor
100%
Cyclooxygenase 2
100%
Wound Healing
50%
Side Effect
50%
Nonsteroid Antiinflammatory Agent
50%
Methapyrilene
50%
Edema
50%